Chris Boshoff

Chris Boshoff is the Chief Scientific Officer at Pfizer, where he plays a pivotal role in the development of innovative pharmaceutical solutions. Recently, he was in the news for announcing the halt of the development of Danuglipron, an experimental weight-loss medication, following reports of liver damage in a patient during trials, despite the patient showing no symptoms or side effects.